Recruiting Myalgic Encephalomyelitis Studies in Chapel Hill
DIALYSIS-TIR Study
This study will look at control of blood sugar levels in persons with type 2 diabetes mellitus currently on chronic dialysis. Researchers will compare blood sugar levels in people taking semaglutide t...
A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes
This is a Phase 2 randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of AK117 or placebo, combined with azacitidine in patients with newly diagnosed hig...
A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)
This is a Phase 2/3, multiregional, two-arm, double-blind, randomized, active (standard-of-care)-controlled study of the efficacy and safety of tividenofusp alfa (DNL310), an investigational central n...
Study of EXE-346 Live Biotherapeutic to Reduce High Bowel Movement Frequency in Subjects With an IPAA (PROF)
The aim of this study is to assess the safety and preliminary efficacy of treatment with EXE-346, a live biotherapeutic, which may reduce bowel movement frequency in patients with an ileal pouch-anal ...
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
This study will enroll participants with myelodysplastic syndromes (MDS) with an Isocitrate dehydrogenase protein, 1 (IDH1) mutation, who have not received treatment with a hypomethylating agent previ...
Daratumumab for Treatment of Proliferative Glomerulonephritis With Monoclonal Immune Deposits
The purpose of this research is to study the safety and efficacy of daratumumab in inducing complete or partial remission in people with proliferative glomerulonephritis with monoclonal immunoglobulin...
About Myalgic Encephalomyelitis Clinical Trials in Chapel Hill
Myalgic encephalomyelitis (ME/CFS) is a complex, chronic illness characterized by profound fatigue, post-exertional malaise, cognitive impairment, and sleep dysfunction. It affects millions worldwide and has no definitive diagnostic test or cure. Research is exploring immune, metabolic, and neurological mechanisms.
There are currently 6 myalgic encephalomyelitis clinical trials recruiting participants in Chapel Hill, NC. These studies are seeking a combined 448 participants. Research is being sponsored by University of Texas Southwestern Medical Center, Akeso, Denali Therapeutics Inc. and 3 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Myalgic Encephalomyelitis Clinical Trials in Chapel Hill — FAQ
Are there myalgic encephalomyelitis clinical trials in Chapel Hill?
Yes, there are 6 myalgic encephalomyelitis clinical trials currently recruiting in Chapel Hill, NC. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Chapel Hill?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Chapel Hill research site will contact you about next steps.
Are clinical trials in Chapel Hill free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Chapel Hill studies also compensate for your time and travel.
What myalgic encephalomyelitis treatments are being tested?
The 6 active trials in Chapel Hill are testing new therapies including novel drugs, biologics, and treatment approaches for myalgic encephalomyelitis.
Data updated March 2, 2026 from ClinicalTrials.gov